These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 33658660)

  • 1. Pathogenesis of cardiovascular events in BCR-ABL1-negative myeloproliferative neoplasms.
    Guy A; Poisson J; James C
    Leukemia; 2021 Apr; 35(4):935-955. PubMed ID: 33658660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evaluation of the relevance of thrombin generation and procoagulant activity in thrombotic risk assessment in BCR-ABL-negative myeloproliferative neoplasm patients.
    Baccouche H; Ben Jemaa M; Chakroun A; Chadi S; Mahjoub S; Sfar I; Gorgi Y; Ben Romdhane N
    Int J Lab Hematol; 2017 Oct; 39(5):502-507. PubMed ID: 28497580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms.
    Reeves BN; Beckman JD
    Curr Hematol Malig Rep; 2021 Jun; 16(3):304-313. PubMed ID: 33876389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms.
    Kissova J; Bulikova A; Ovesna P; Bourkova L; Penka M
    Int J Hematol; 2014 Nov; 100(5):429-36. PubMed ID: 25227185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pathogenesis of thrombosis in JAK2V617F myeloproliferative neoplasms].
    Guy A; James C
    Med Sci (Paris); 2019; 35(8-9):651-658. PubMed ID: 31532377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): A retrospective single-center study of 829 MPN patients.
    Wille K; Huenerbein K; Jagenberg E; Sadjadian P; Becker T; Kolatzki V; Meixner R; Marchi H; Fuchs C; Griesshammer M
    Eur J Haematol; 2022 Feb; 108(2):154-162. PubMed ID: 34719056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
    Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
    Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Level of Circulating Microparticles in Patients with BCR/ABL Negative Myeloproliferative Neoplasm - a Pilot Study.
    Aswad MH; Kissová J; Rihova L; Zavrelova J; Ovesná P; Penka M
    Klin Onkol; 2019; 32(2):109-116. PubMed ID: 30995850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence, characteristics and risk factors of thromboembolic events in East Asian patients with BCR-ABL1 negative myeloproliferative neoplasms.
    Kim J; Byun JM; Hong J; Koh Y; Shin DY; Kim I; Yoon SS; Park H; Bang SM
    Sci Rep; 2021 Sep; 11(1):17819. PubMed ID: 34497309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular risk in a contemporary cohort of patients with myeloproliferative neoplasms'.
    Mehta D; Alimam S; McLornan DP; Henry JA; Ahmed S; Ghosh AK; Tyebally S; Walker JM; Patel R; Amerikanou R; O'Nions J; Wilson AJ; Lambert J; Sekhar M; Chen D
    Curr Res Transl Med; 2024 Mar; 72(1):103420. PubMed ID: 38262189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and Molecular Attributes of Patients With BCR/ABL1-negative Myeloproliferative Neoplasms in India: Real-world Data and Challenges.
    Singh S; Kaur K; Paul D; Jain K; Singh J; Narang V; Garg B; Sood N; Dhillon B
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e569-e578. PubMed ID: 33757770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms.
    Mughal TI; Vannucchi AM; Soverini S; Bazeos A; Tibes R; Saglio G; Abdel-Wahab O; Pardanani A; Hehlmann R; Barbui T; Van Etten R; Tefferi A; Goldman JM
    Haematologica; 2014 May; 99(5):797-801. PubMed ID: 24790057
    [No Abstract]   [Full Text] [Related]  

  • 13. Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy.
    Griesshammer M; Sadjadian P; Wille K
    Expert Rev Hematol; 2018 Sep; 11(9):697-706. PubMed ID: 30084669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Thrombosis and platelet dysfunction in myeloproliferative neoplasms].
    Mornet C; Galinat H; Mingant F; Ianotto JC; Lippert E
    Rev Med Interne; 2020 May; 41(5):319-324. PubMed ID: 32008800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives.
    Krecak I; Verstovsek S; Lucijanic M
    Ann Hematol; 2024 May; 103(5):1513-1523. PubMed ID: 37665349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Sankar K; Stein BL; Rampal RK
    Cancer Treat Res; 2019; 179():159-178. PubMed ID: 31317487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH).
    Appelmann I; Kreher S; Parmentier S; Wolf HH; Bisping G; Kirschner M; Bergmann F; Schilling K; Brümmendorf TH; Petrides PE; Tiede A; Matzdorff A; Griesshammer M; Riess H; Koschmieder S
    Ann Hematol; 2016 Apr; 95(5):707-18. PubMed ID: 26916570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort.
    Kander EM; Raza S; Zhou Z; Gao J; Zakarija A; McMahon BJ; Stein BL
    Int J Hematol; 2015 Nov; 102(5):587-93. PubMed ID: 26440973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2 mutation and thrombosis in the myeloproliferative neoplasms.
    Vannucchi AM
    Curr Hematol Malig Rep; 2010 Jan; 5(1):22-8. PubMed ID: 20425393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis.
    Gianelli U; Iurlo A; Cattaneo D; Bossi A; Cortinovis I; Augello C; Moro A; Savi F; Castelli R; Brambilla C; Bianchi P; Primignani M; Cortelezzi A; Bosari S
    Leuk Res; 2015 May; 39(5):525-9. PubMed ID: 25840747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.